Research finds new therapy options for children with severe juvenile idiopathic arthritis
Systemic juvenile idiopathic arthritis (SJIA) has long been considered a therapeutic orphan. Until now, the principal effective treatment has been high-dose steroids (prednisone) which are accompanied by several serious side effects. Newer treatments for other forms of JIA have not been as successful for the systemic subtype.
SJIA, an inflammatory disease, accounts for approximately 15 per cent of all children with juvenile idiopathic arthritis there are currently approximately 60 children followed with SJIA at SickKids. High fever, skin rashes, and swelling of the joints and inflammation of internal organs such as heart, liver, spleen and lymph nodes are some of the symptoms that children with SJIA face daily.
Two recent studies in the New England Journal of Medicine have assessed other treatment options for these patients and found two biologic drugs to be safe and effective therapies for children with SJIA. In both studies, many children who were treated with these drugs not only achieved a status of inactive disease (no fever, no joint inflammation) but also showed a reduction or discontinuation steroid use.
Both international studies were conducted by the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG), which the Rheumatology Faculty at The Hospital for Sick Children (SickKids) and University of Toronto are members of. Dr. Rayfel Schneider was one of the co-investigators of both of these studies and the lead SickKids investigator.
"This group of patients is typically very challenging to treat. This research is a major step towards improved therapy options that are safe and effective." says Dr. Rayfel Schneider, Staff Physician and Project Investigator in the Department of Rheumatology at SickKids. "No unanticipated side effects were observed and those that did occur are also seen with other medications in this class."
Each therapy works by blocking specific molecules that are involved in the development and persistence of inflammation. The molecules called Interleukin-6 and Interleukin-1 have been found to be central to the pathogenesis of SJIA.
In one of the randomized controlled trials, a biologic called tocilizumab was administered to target the Interleukin-6 receptor. This study provides the first evidence in a controlled setting involving a large number of patients from around the world that blocking the action of Interleukin-6 with tocilizumab is highly effective, and safe, in patients with severe and persistent SJIA. After one year of treatment, one third of the patients reached clinically inactive disease and approximately half had stopped taking oral corticosteroids. This study was conducted at 43 centres worldwide.
In the other study the efficacy and safety of a biologic called canakinumab was assessed. Canakinumab selectively binds to Interleukin-1 beta and inactivates the signaling that leads to inflammation. The study was divided into two clinical trials; the first to provide evidence that the drug is effective in controlling fever and arthritis, and the second to further investigate the efficacy and safety of canakinumab in SJIA with active systemic features and the ability to reduce the dose of prednisone. The study demonstrated that even a single injection of the drug can result in inactive disease in as few as 15 days among 32 per cent of the treated patients. And after just seven months of treatment the drug allowed for discontinuation of steroid treatment for 45 per cent of the patients.
Overall, both therapeutic approaches proved to be safe and effective. "This appears to be a major step forward in the treatment of children with SJIA and may lead to a change in the outcome of a difficult-to-manage, and potentially fatal disease," says Dr. Schneider.
Journal reference: New England Journal of Medicine
Provided by SickKids
- Not all juvenile arthritis is the same Oct 22, 2012 | not rated yet | 0
- Pulmonary complications often fatal in systemic JIA Nov 19, 2012 | not rated yet | 0
- New clinical practice guidelines developed for juvenile idiopathic arthritis Mar 30, 2011 | not rated yet | 0
- Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment May 30, 2012 | not rated yet | 0
- Children with juvenile arthritis have higher rates of bacterial infection May 01, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Is energy convertible to matter?
1 hour ago Can we convert energy to matter?
Rotating electron as a dipole is this right?
3 hours ago An electron as shown by the Stern Gerlach experiment behaves like a dipole (albeit only in one of two states). I have been trying to figure out how...
Dipole term in multipole expansion
7 hours ago Hi. I'm having some difficult in understanding something about the dipole term in a multipole expansion. Griffiths writes the expansion as a sum of...
Bubbles in a Pre-Boiling/Boiling pot of water
8 hours ago How is it that bubbles form on the bottom of a surface of a pot of boiling water? I think that there is probably an elementary answer to this...
Assumptions of Griffith's fracture theory
19 hours ago Any experts on Griffith's fracture theory? I am studying the subject and I am having hard time finding out if the theory is valid for all possible...
Current leading voltage or vice versa concept
21 hours ago Hello, I was wondering if there is a conceptual explanation for when current leads voltage or vice versa for capacitors or inductors with AC...
- More from Physics Forums - Classical Physics
More news stories
(HealthDay)—Injections of a sugar solution appear to help relieve knee pain and stiffness related to osteoarthritis, a new study suggests.
Arthritis & Rheumatism 14 hours ago | 4 / 5 (1) | 0 |
A novel study reports that white men and women of European descent inherit common foot disorders, such as bunions (hallux valgus) and lesser toe deformities, including hammer or claw toe. Findings from the Framingham Foot ...
Arthritis & Rheumatism May 20, 2013 | not rated yet | 0 |
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
Arthritis & Rheumatism May 19, 2013 | 4.9 / 5 (7) | 0 |
(HealthDay)—Compared to clinical diagnosis of synovitis, ultrasound-detected synovitis provides either improved sensitivity or specificity when used with the American College of Rheumatology/European League ...
Arthritis & Rheumatism May 15, 2013 | not rated yet | 0
(HealthDay)—A genome-wide linkage scan has identified the chromosome 17p11.2-q11.2 region as the susceptibility locus for fibromyalgia, according to research published in the April issue of Arthritis & ...
Arthritis & Rheumatism May 11, 2013 | not rated yet | 0
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
10 hours ago | 4 / 5 (4) | 0 |
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
8 hours ago | 4.8 / 5 (6) | 0 |
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
3 hours ago | 5 / 5 (1) | 0
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
4 hours ago | 5 / 5 (3) | 0 |
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
5 hours ago | not rated yet | 0 |
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
10 hours ago | 4.8 / 5 (4) | 0 |